The FDA has approved Ozempic (semaglutide) injection for the treatment of adults with type 2 diabetes.
Indications: Ozempic is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is not recommended as first-line therapy for patients inadequately controlled on diet and exercise.
Dosage and administration: Inject subcutaneously in the abdomen, thigh, or upper arm. Start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycemic control is needed, increase to 1 mg once weekly. Administer once weekly at any time of day, with or without meals. If a dose is missed, administer within 5 days of missed dose.
Adverse reactions: The most common adverse reactions (≥5% of patients) are nausea, vomiting, diarrhea, abdominal pain, and constipation.
Novo Nordisk receives FDA approval of OZEMPIC (semaglutide) injection for the treatment of adults with type 2 diabetes. [news release]. Novo Nordisk; Plainsboro, NJ; December 5, 2017. http://press.novonordisk-us.com/2017-12-5-Novo-Nordisk-Receives-FDA-Appr.... Accessed December 8, 2017.
This Week's Must Reads
Chronic Pain Among Suicide Decedents, Ann Intern Med; ePub 2018 Sep 11; Petrosky, et al
Pain and ED Use in Adults with Dementia, J Pain Symptom Manage; ePub 2018 Sep 14; Hunt, et al
Higher Optimism Predicts Lower Pain Reduction, J Pain; ePub 2018 Sep 13; Hinkle, Quiton
QOL in Patients with Chronic & Episodic Migraine, Pain Medicine; ePub 2018 Sep 14; Ceylan, et al
LIDAS as a Valid Measure for Chronic Pain, J Pain; ePub 2018 Aug 30; Wilson, et al
Must Reads in Diabetes
Statins for Prevention of CVD in the Elderly , BMJ; ePub 2018 Sep 5; Ramos, Comas-Cuff, et al
GD & Maternal Disorders of Glucose Metabolism, JAMA; 2018 Sep 11; Lowe, Scholtens, et al
Treatment Intensification Guidelines for T2D , Ann Intern Med; ePub 2018 Sep 4; Roglic, et al
Prevalence of Diabetes Among US Adults, BMJ; ePub 2018 Aug 27; Xu, Liu, et al
Aspirin for Primary CV Prevention in Diabetes, N Engl J Med; ePub 2018 Aug 26; ASCEND Study Collaborative Group